

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/023279 A1

(51) International Patent Classification:

A61K 31/454 (2006.01) A61K 45/06 (2006.01)
A61K 31/635 (2006.01) A61P 35/02 (2006.01)
A61K 31/7068 (2006.01)

(21) International Application Number:

PCT/EP2023/070946

(22) International Filing Date:

28 July 2023 (28.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22460034.6 29 July 2022 (29.07.2022) EP

(71) Applicants: **RYVU THERAPEUTICS S.A.** [PL/PL];
Leona Henryka Sternbacha 2, 30-394 Kraków (PL).
BERLIN-CHEMIE AG [DE/DE]; Glienicker Weg 125,
12489 Berlin (DE).

(72) Inventors: **BINASCHI, Monica**; c/o Menarini Ricerche
S.p.A., Via Tito Speri 12, 00040 Pomezia (IT). **BEL-**

LAROSA, Daniela; c/o Menarini Ricerche S.p.A., Via Tito
Speri 12, 00040 Pomezia (IT). **MERLINO, Giuseppe**;
c/o Menarini Ricerche S.p.A., Via Tito Speri 12, 00040
Pomezia (IT). **BALDINI, Simone**; c/o Menarini Industrie
Farmaceutiche Riunite Srl, Via Dei Sette Santi 1/3, 50131
Firenze (IT). **RZYMSKI, Tomas**; c/o Ryvu Therapeutics
S.A., Leona Henryka Sternbacha 2, 30-394 Kraków (PL).

(74) Agent: **MAIWALD GMBH**; Andreas Ledl, Elisenhof,
Elisenstraße 3, 80335 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CANCER COMBINATION THERAPY INCLUDING A BCL-2 INHIBITOR




FIG. 1

(57) Abstract: The present invention is inter alia concerned with a combination of (i) a BCL-2 inhibitor and (ii) SEL24/MEN1703 for use as medicament, preferably for use in the treatment of a patient suffering from cancer. The present invention is also concerned with a kit of dosage forms comprising (i) a dosage form comprising a BCL-2 inhibitor and (ii) a dosage form comprising SEL24/MEN1703; as well as dosage form comprising (i) a BCL-2 inhibitor and (ii) SEL24/MEN1703.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))